The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study (VEG108838) of lapatanib plus pazopanib (L+P) versus lapatanib (L) in patients with ErbB2+ inflammatory breast cancer (IBC).
Massimo Cristofanilli
No relevant relationships to disclose
Stephen R. D. Johnston
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Alexey Manikhas
Research Funding - GlaxoSmithKline
Henry Leonidas Gomez
No relevant relationships to disclose
Oleg Gladkov
Research Funding - GlaxoSmithKline
Zhimin Shao
No relevant relationships to disclose
Sufia Safina
Research Funding - GlaxoSmithKline
Stephen D. Rubin
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Sulabha Ranganathan
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Suman Lata
Employment or Leadership Position - GlaxoSmithKline
Maureen E. Trudeau
Honoraria - GlaxoSmithKline